Venova Barrier Device
- User: Female
- Hormonal: Non-Hormonal
-
Delivery type:
- Barrier
-
Intended Duration:
- Long-Acting
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): Venova Technologies
Details
-
Mechanism of Action:
- Physical Barrier
- Inactive Materials: Not Yet Determined
- Regimen: Not Yet Determined
- MPT: Not Potential MPT
- Promising Attributes: This device is non-hormonal and copper-free and so has the potential to have very few side effects.
Product Status
Active Pre-Clinical Research
History
2022: In a 2-week pilot study in baboons, this device was safely and tolerably worn through menses and a patent was filed for the device.
2023: Start of an NIH STTR Phase I Grant to continue with biocompatibility testing.
2025: Venova announces receipt of a $2.23M SBIR Phase II grant from NIH to support pre-IND development of the cervical barrier device.